Kodiak Sciences INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Kodiak Sciences reports significant clinical trial advancements for its retinal disease pipeline, including successful Phase 3 studies for Zenkuda, alongside substantial net losses and going concern doubt.
NASDAQ
Kodiak Sciences announces its 2024 financial results and provides updates on its clinical programs targeting retinal diseases, including tarcocimab, KSI-501, and KSI-101.
NASDAQ
Kodiak Sciences reports positive results from key clinical trials and progress in manufacturing, while also detailing financial performance for the year ended December 31, 2023.